MOR.DE - MorphoSys AG
| Previous Close | 104.30 |
| Open | 102.00 |
| Bid | 99.10 x 1500 |
| Ask | 99.20 x 8800 |
| Day's Range | 97.50 - 102.40 |
| 52 Week Range | 79.70 - 146.30 |
| Volume | 292,080 |
| Avg. Volume | 157,139 |
| Market Cap | 3.135B |
| Beta (5Y Monthly) | 1.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.04 |
| Earnings Date | Mar 18, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 107.55 |
- ACCESSWIRE
MorphoSys Initiates Expanded Access Program for Tafasitamab in the U.S.
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / February 4, 2020 / MorphoSys AG (FSE:MOR); Prime Standard Segment; MDAX & TecDAX; (NASDAQ:MOR) announced today the initiation of an expanded access program (EAP) ...
- Simply Wall St.
MorphoSys AG's (ETR:MOR) Path To Profitability
MorphoSys AG's (ETR:MOR): MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and...
- ACCESSWIRE
MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 13, 2020 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announces that it today has entered into a global collaboration and ...
- ACCESSWIRE
MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 30, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) announced today that it has submitted a Biologics License Application ...
- ACCESSWIRE
First Patient Dosed in Phase 1 Clinical Study of Tafasitamab in Firstline DLBCL
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 27, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced that the first patient has been dosed in a phase 1b ...
- Insider Monkey
Is MorphoSys AG (MOR) A Good Stock To Buy?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
- ACCESSWIRE
MorphoSys AG: Corporate Calendar 2020
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 12, 2019 / MorphoSys (NASDAQ:MOR) (FSE:MOR): Dear Madam/Sir, Please note MorphoSys's financial reporting dates 2020 as follows: For a direct import of the ...
- Reuters
Chief scientist quits at Germany's Morphosys ahead of product launch
Morphosys' chief scientific officer will quit after 17 years with the group, the latest change at the top of the German biotech firm as it gears up for its first product launch. The group said late on Wednesday that CSO Markus Enzelberger would step down at the end of February to explore new opportunities. The shares dropped 2.1% at 0853 GMT on Thursday as one trader pointed to Enzelberger's "crucial position" at Morphosys.
- ACCESSWIRE
Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His Departure
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 20, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced that Dr. Markus Enzelberger, the company's Chief Scientific Officer (CSO), has decided to step down as CSO and member of the company's Management Board to explore new opportunities. Dr. Enzelberger will leave MorphoSys on February 29, 2020.
- ACCESSWIRE
MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis
IDMC recommends to increase patient number from currently 330 to 450. MARTINSRIED, GERMANY / ACCESSWIRE / November 18, 2019 / MorphoSys (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) today announced that the ongoing tafasitamab phase 3 B-MIND study has successfully passed the pre-planned, event-driven interim analysis for futility. An independent data monitoring committee (IDMC) reviewed the data and recommended to increase the number of patients from currently 330 to 450.
- ACCESSWIRE
MorphoSys Continues to Build Commercial Presence by Opening new U.S. Headoffice
PLANEGG/MUNICH, GERMANY and BOSTON MA / ACCESSWIRE / November 15, 2019 / MorphoSys (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today the opening of its new U.S. headoffice. ...
- Simply Wall St.
MorphoSys (ETR:MOR) Shareholders Have Enjoyed An Impressive 116% Share Price Gain
MorphoSys AG (ETR:MOR) shareholders might be concerned after seeing the share price drop 10% in the last quarter. But...
- Thomson Reuters StreetEvents
Edited Transcript of MOR.DE earnings conference call or presentation 30-Oct-19 1:00pm GMT
Q3 2019 Morphosys AG Earnings Call
- ACCESSWIRE
Results for Bimagrumab in Obesity and Type 2 Diabetes Presented by MorphoSys's Partner
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 11, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Novartis presented phase 2 results ...
- ACCESSWIRE
MorphoSys to Present Data on Tafasitamab at ASH 2019 Meeting
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 6, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) today announced presentation of so far unpublished data on tafasitamab, ...
- ACCESSWIRE
MorphoSys AG Reports Third Quarter 2019 Financial Results
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 29, 2019 / MorphoSys AG Reports Third Quarter 2019 Financial Results Conference call and webcast (in English) to be held on October 30, 2019 at 2:00pm CET ...
- ACCESSWIRE
MorphoSys AG: Ad hoc: Primary Endpoint Met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide Compared to Lenalidomide Alone
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 29, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) today announced topline results from the primary analysis of the retrospective ...
- ACCESSWIRE
MorphoSys AG: Primary Endpoint Met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide Compared to Lenalidomide Alone
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 29, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR): Primary endpoint met: Statistically significant superior best objective ...
- ACCESSWIRE
MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility
NASDAQ:MOR) today announced the end of the clinical development program of MOR106 in atopic dermatitis. The joint decision of all three involved parties, Galapagos NV, MorphoSys AG and Novartis Pharma AG, was based on an interim analysis for futility that was performed in the Phase 2 IGUANA trial. The clinical development program of MOR106 in atopic dermatitis included the two Phase 2 studies IGUANA and GECKO, as well as a Phase 1 bridging study for subcutaneous formulation and a Japanese ethno-bridging study.
- ACCESSWIRE
MorphoSys AG: MOR106 Clinical Development in Atopic Dermatitis Stopped
NASDAQ: MOR) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the end of the clinical development program of MOR106 in atopic dermatitis. The joint decision of all three involved parties, Galapagos NV, MorphoSys AG and Novartis Pharma AG, was based on an interim analysis for futility that was performed in the Phase 2 IGUANA trial. The clinical development program of MOR106 in atopic dermatitis included the two Phase 2 studies IGUANA and GECKO, as well as a Phase 1 bridging study for subcutaneous formulation and a Japanese ethno-bridging study.
- Insider Monkey
Did Hedge Funds Drop The Ball On MorphoSys AG (MOR) ?
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the first […]
- ACCESSWIRE
Invitation to MorphoSys Q3 2019 Conference Call on October 30, 2019
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 21, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ:MOR) will publish its first nine months' 2019 results on October 29, 2019 ...
- Thomson Reuters StreetEvents
Edited Transcript of MOR.DE earnings conference call or presentation 7-Aug-19 12:00pm GMT
Half Year 2019 Morphosys AG Earnings Call
- ACCESSWIRE
MorphoSys and I-Mab Biopharma Announce IND Clearance to Initiate Clinical Trials of MOR202/TJ202 for the Treatment of Multiple Myeloma in Mainland China
NASDAQ:MOR) and I-Mab Biopharma (I-Mab) announced today that I-Mab has received Investigational New Drug (IND) clearances from the National Medical Products Administration (NMPA) of China to expand the ongoing phase 2 and 3 clinical trials of MOR202/TJ202, MorphoSys's human monoclonal anti-CD38 antibody for the treatment of multiple myeloma (MM), also to mainland China.
- ACCESSWIRE
MorphoSys to Present at Upcoming Investor Conferences
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / September 18, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will present at the following conferences: Baader Investment Conference ...
